Literature DB >> 11139804

Antithrombotic therapy for prosthetic valves: routine treatment and special considerations.

A M Al-Ahmad1, D Hartnett-Daudelin, D N Salem.   

Abstract

The use of prosthetic heart valves has increased over the past 3 decades. Antithrombotic agents remain the mainstay of therapy to prevent thromboembolic events caused by the presence of a prosthetic heart valve. We examine the risks of thromboembolic events as well as the risks and benefits of antithrombotic therapy in patients with mechanical and bioprosthetic heart valves. We also review the data regarding the use of antithrombotic therapy in special groups of patients, such as those with intracranial bleeding, pregnant women with prosthetic heart valves, and patients with prosthetic heart valves undergoing surgery.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11139804     DOI： 10.1007/s11886-001-0015-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  45 in total

1.  Comparison of high-dose with low-dose aspirin in patients with mechanical heart valve replacement treated with oral anticoagulant.

Authors:  R Altman; J Rouvier; E Gurfinkel; A Scazziota; A G Turpie
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

2.  AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves.

Authors:  J Acar; B Iung; J P Boissel; M M Samama; P L Michel; J P Teppe; J C Pony; H L Breton; D Thomas; R Isnard; G de Gevigney; E Viguier; A Sfihi; G Hanania; M Ghannem; A Mirode; C Nemoz
Journal:  Circulation       Date:  1996-11-01       Impact factor: 29.690

Review 3.  Prosthetic heart valves.

Authors:  W Vongpatanasin; L D Hillis; R A Lange
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

Review 4.  Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Authors:  B J Sanson; A W Lensing; M H Prins; J S Ginsberg; Z S Barkagan; E Lavenne-Pardonge; B Brenner; M Dulitzky; J D Nielsen; Z Boda; S Turi; M R Mac Gillavry; K Hamulyák; I M Theunissen; B J Hunt; H R Büller
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

5.  Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves.

Authors:  N Vitale; M De Feo; L S De Santo; A Pollice; N Tedesco; M Cotrufo
Journal:  J Am Coll Cardiol       Date:  1999-05       Impact factor: 24.094

6.  Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: a 23-year population-based study.

Authors:  K C Huber; B J Gersh; K R Bailey; H V Schaff; D O Hodge; R H Cha; J H Chesebro
Journal:  Mayo Clin Proc       Date:  1997-12       Impact factor: 7.616

Review 7.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

Authors:  P D Stein; J S Alpert; J E Dalen; D Horstkotte; A G Turpie
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

8.  Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).

Authors:  R O Bonow; B Carabello; A C de Leon; L H Edmunds; B J Fedderly; M D Freed; W H Gaasch; C R McKay; R A Nishimura; P T O'Gara; R A O'Rourke; S H Rahimtoola; J L Ritchie; M D Cheitlin; K A Eagle; T J Gardner; A Garson; R J Gibbons; R O Russell; T J Ryan; S C Smith
Journal:  Circulation       Date:  1998-11-03       Impact factor: 29.690

Review 9.  Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.

Authors:  S C Cannegieter; F R Rosendaal; E Briët
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

10.  Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

Authors:  J N Saour; J O Sieck; L A Mamo; A S Gallus
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.